| Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
|
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Germline mutations in MDS/AML predisposition disorders |
|
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
|
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |
| Detectable mutations precede late myeloid neoplasia in aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
